Skip to main content
JAGX
NASDAQ Life Sciences

Jaguar Health Issues Shares to Convert Preferred Stock, Adjourns Annual Meeting Amidst Dilution Concerns

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$2.9
Mkt Cap
$1.168M
52W Low
$2.53
52W High
$171.5
Market data snapshot near publication time

summarizeSummary

Jaguar Health issued common stock to convert preferred shares, causing significant dilution, and adjourned its annual meeting to address shareholder concerns over pending proposals.


check_boxKey Events

  • Significant Dilution from Preferred Stock Conversion

    Jaguar Health issued 54,222 common shares to Streeterville Capital, LLC in exchange for 7.96 shares of Series Q Perpetual Preferred Stock, which were then cancelled. This transaction, valued at approximately $157,244 based on the current stock price, represents a substantial dilution for existing common shareholders.

  • Annual Meeting Adjourned for Additional Information

    The company adjourned its 2026 Annual Meeting of Stockholders until June 2, 2026. The adjournment is to provide additional information to stockholders regarding certain proposals in the definitive proxy statement, which previously included highly dilutive financing agreements. This indicates potential difficulties in gaining shareholder approval for critical capital structure changes.


auto_awesomeAnalysis

Jaguar Health issued common stock to Streeterville Capital, LLC, converting preferred shares and resulting in significant dilution for existing shareholders. This transaction, valued at approximately $157,244, represents a substantial portion of the company's current market capitalization. Concurrently, the company adjourned its annual meeting, citing a need to provide additional information regarding proposals in its proxy statement. This suggests potential challenges in securing shareholder approval for critical financing or capital structure changes, which have previously included highly dilutive agreements.

At the time of this filing, JAGX was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $2.53 to $171.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed JAGX - Latest Insights

JAGX
May 22, 2026, 5:22 PM EDT
Filing Type: 8-K
Importance Score:
8
JAGX
May 20, 2026, 4:36 PM EDT
Filing Type: 8-K
Importance Score:
10
JAGX
May 20, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
JAGX
May 20, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
7
JAGX
May 19, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
9
JAGX
May 19, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
JAGX
May 08, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
7
JAGX
May 07, 2026, 2:59 PM EDT
Filing Type: 8-K
Importance Score:
8
JAGX
May 06, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
JAGX
May 04, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
8